Systemic inflammation after myocardial infarction.

2013 REFERENCES 1. Owen WG, Esmon CT: Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1981; 256:5532–5535 2. Conway EM: Thrombomodulin and its role in inflammation. Semin Immunopathol 2012; 34:107–125 3. Lin SM, Wang YM, Lin HC, et al: Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Crit Care Med 2008; 36:683–689 4. Coughlin SR, Camerer E: PARticipation in inflammation. J Clin Invest 2003; 111:25–27 5. Fink MP: Bench-to-bedside review: High-mobility group box 1 and critical illness. Crit Care 2007; 11:229 6. Abeyama K, Stern DM, Ito Y, et al: The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115:1267–1274 7. Ito T, Kawahara K, Okamoto K, et al: Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 2008; 28:1825–1830 8. Uchiba M, Okajima K, Murakami K, et al: Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation. Am J Physiol 1996; 271(3, Part 1):L470–L475 9. Hagiwara S, Iwasaka H, Matsumoto S, et al: In vivo and in vitro effects of the anticoagulant, thrombomodulin, on the inflammatory response in rodent models. Shock 2010; 33:282–288 10. Nagato M, Okamoto K, Abe Y, et al: Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia. Crit Care Med 2009; 37:2181–2186 11. Saito H, Maruyama I, Shimazaki S, et al: Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: Results of a phase III, randomized, doubleblind clinical trial. J Thromb Haemost 2007; 5:31–41 12. Yamakawa K, Fujimi S, Mohri T, et al: Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: A historical control study. Crit Care 2011; 15:R123 13. Kato T, Sakai T, Kato M, et al: Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: A retrospective cohort study. Thromb J 2013; 11:3 14. Ogawa Y, Yamakawa K, Ogura H, et al: Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Care Surg 2012; 72:1150–1157 15. Vincent J-L, Ramesh MK, Ernest D, et al: A Randomized, DoubleBlind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation. Crit Care Med 2013; 41:2069–2079 16. Ranieri VM, Thompson BT, Barie PS, et al; PROWESS-SHOCK Study Group: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055–2064 17. Opal SM, Laterre PF, Francois B, et al; ACCESS Study Group: Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial. JAMA 2013; 309:1154–1162 18. Guntupalli K, Dean N, Morris PE, et al; TLF LF-0801 Investigator Group: A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit Care Med 2013; 41:706–716 19. Wunderink RG, Laterre PF, Francois B, et al; CAPTIVATE Trial Group: Recombinant tissue factor pathway inhibitor in severe communityacquired pneumonia: A randomized trial. Am J Respir Crit Care Med 2011; 183:1561–1568